Crucell, MedImmune enter research, license collaboration |
|
|
|
Published
:
Mon, 15 Oct 2007 07:09
|
AMSTERDAM (Thomson Financial) - Crucell NV said it and MedImmune have entered into an exclusive license and research collaboration to develop and commercialise one of Crucell's panels of bacterial antibodies primarily for the treatment and prevention of hospital-acquired bacterial infection.Under the agreement, MedImmune will give Crucell upfront, annual and milestone payments potentially exceeding 40 mln usd, plus research and development funding as well as an undisclosed royalty on product sales.cornelia.messing@thomson.comcmm/vlbCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Crucell says Phase I studies of anti-rabies cocktail show 'progress' 